0001807120false00018071202024-06-132024-06-13

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 13, 2024

 

 

Design Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

 

Delaware

001-40288

82-3929248

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

6005 Hidden Valley Road

Suite 110

 

Carlsbad, California

 

92011

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (858) 293-4900

 

N/A

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, $0.0001 par value per share

 

DSGN

 

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

 

 

Item 5.07

Submission of Matters to a Vote of Security Holders.

 

On June 13, 2024, Design Therapeutics, Inc. (the “Company”) held its 2024 Annual Meeting of Stockholders (the “Annual Meeting”). As of April 18, 2024, the record date for the Annual Meeting, 56,495,039 shares of common stock were outstanding and entitled to vote at the Annual Meeting. A summary of the matters voted upon by stockholders at the Annual Meeting is set forth below. Voting results are, where applicable, reported by rounding fractional share voting down to the nearest whole number.

Proposal 1. Election of Directors

The Company’s stockholders elected the one person listed below as a Class III Director, to serve until the Company’s 2027 Annual Meeting of Stockholders and until his successor is duly elected and qualified. The final voting results are as follows:

 

 

Votes For

 

Votes Withheld

 

Broker Non-Votes

Pratik Shah, Ph.D.

 

42,785,096

 

3,511,039

 

7,688,435

Proposal 2. Ratification of Selection of Independent Registered Public Accounting Firm

The Company’s stockholders ratified the selection by the Audit Committee of the Company’s Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024. The final voting results are as follows:

Votes For

 

Votes Against

 

Abstentions

 

Broker Non-Votes

53,981,806

 

2,764

 

2

 

Not applicable

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

DESIGN THERAPEUTICS, INC.

 

 

 

 

Date:

June 17, 2024

By:

/s/ Pratik Shah, Ph.D.

 

 

 

Pratik Shah, Ph.D.
President, Chief Executive Officer and Chairperson

 

v3.24.1.1.u2
Document And Entity Information
Jun. 13, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 13, 2024
Entity Registrant Name Design Therapeutics, Inc.
Entity Central Index Key 0001807120
Entity Emerging Growth Company true
Entity File Number 001-40288
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 82-3929248
Entity Address, Address Line One 6005 Hidden Valley Road
Entity Address, Address Line Two Suite 110
Entity Address, City or Town Carlsbad
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92011
City Area Code (858)
Local Phone Number 293-4900
Entity Information, Former Legal or Registered Name N/A
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Ex Transition Period true
Title of 12(b) Security Common Stock, $0.0001 par value per share
Trading Symbol DSGN
Security Exchange Name NASDAQ
Grafico Azioni Design Therapeutics (NASDAQ:DSGN)
Storico
Da Mag 2024 a Giu 2024 Clicca qui per i Grafici di Design Therapeutics
Grafico Azioni Design Therapeutics (NASDAQ:DSGN)
Storico
Da Giu 2023 a Giu 2024 Clicca qui per i Grafici di Design Therapeutics